Business Context and Reporting Period
This Form 8-K was filed by MEI Pharma, Inc. on November 6, 2012. The registrant is a Delaware corporation focused on developing investigational oral histone deacetylase (HDAC) inhibitors. The report details a significant clinical development milestone regarding the company's lead candidate, Pracinostat.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical trial update and does not contain financial statements.
Material Changes and Clinical Developments
- Clinical Data Acceptance: Preliminary data from a pilot Phase II clinical trial of Pracinostat in combination with azacitidine for patients with advanced myelodysplastic syndrome (MDS) was accepted for poster presentation at the American Society of Hematology Annual Meeting on December 10, 2012.
- Study Details: The abstract, submitted by researchers from MD Anderson Cancer Center, reports "very high rates of clinical and cytogenetic response" in high-risk MDS patients.
- Financing Context: The clinical progress is noted in conjunction with a planned equity financing announced on November 5, 2012.
Guidance, Outlook, and Management Commentary
Management expects to initiate a randomized Phase II trial of Pracinostat in combination with azacitidine for MDS patients by the second quarter of 2013. This timeline is contingent upon the successful completion of the equity financing announced the prior day.
Investor Verification Checklist
- Verify the status and terms of the equity financing announced on November 5, 2012, to confirm funding for the upcoming Phase II trial.
- Review the full abstract presented at the American Society of Hematology Annual Meeting on December 10, 2012, for detailed efficacy and safety data.
- Confirm the regulatory status of Pracinostat and the specific patient population criteria for the planned randomized Phase II trial.